美国斯隆·凯特琳纪念癌症中心William D. Tap联合英国皇家马斯登NHS基金会信托基金和癌症研究所Robin L. Jones团队近日取得一项新成果。他们探讨了阿霉素+Olaratumab与阿霉素+安慰剂对晚期软组织肉瘤患者生存期的影响。该研究于2020年4月7日发表在《美国医学会杂志》上。
Title: Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial
Author: William D. Tap, Andrew J. Wagner, Patrick Schffski, Javier Martin-Broto, Anders Krarup-Hansen, Kristen N. Ganjoo, Chueh-Chuan Yen, Albiruni R. Abdul Razak, Alexander Spira, Akira Kawai, Axel Le Cesne, Brian A. Van Tine, Yoichi Naito, Se Hoon Park, Alexander Fedenko, Zsuzsanna Pápai, Victoria Soldatenkova, Ashwin Shahir, Gary Mo, Jennifer Wright, Robin L. Jones
Abstract: Importance Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In a phase 2 study, an overall survival benefit in this population was observed with the addition of olaratumab to doxorubicin over doxorubicin alone.
Objective To determine the efficacy of doxorubicin plus olaratumab in patients with advanced/metastatic STS.
Design, Setting, and Participants ANNOUNCE was a confirmatory, phase 3, double-blind, randomized trial conducted at 110 sites in 25 countries from September 2015 to December 2018; the final date of follow-up was December 5, 2018. Eligible patients were anthracycline-naive adults with unresectable locally advanced or metastatic STS, an Eastern Cooperative Oncology Group performance status of 0 to 1, and cardiac ejection fraction of 50% or greater.
Interventions Patients were randomized 1:1 to receive doxorubicin, 75 mg/m2 (day 1), combined with olaratumab (n=258), 20 mg/kg in cycle 1 and 15 mg/kg in subsequent cycles, or placebo (n=251) on days 1 and 8 for up to 8 21-day cycles, followed by olaratumab/placebo monotherapy.
Main Outcomes and Measures Dual primary end points were overall survival with doxorubicin plus olaratumab vs doxorubicin plus placebo in total STS and leiomyosarcoma (LMS) populations.
Results Among the 509 patients randomized (mean age, 56.9 years; 58.2% women; 46.0% with LMS), all were included in the primary analysis and had a median length of follow-up of 31 months. No statistically significant difference in overall survival was observed between the doxorubicin plus olaratumab group vs the doxorubicin plus placebo group in either population (total STS: hazard ratio, 1.05 [95% CI, 0.84-1.30], P=.69, median overall survival, 20.4 months vs 19.7 months; LMS: hazard ratio, 0.95 [95% CI, 0.69-1.31], P=.76, median overall survival, 21.6 months vs 21.9 months). Adverse events of grade 3 or greater reported in 15% or more of total patients with STS were neutropenia (46.3% vs 49.0%), leukopenia (23.3% vs 23.7%), and febrile neutropenia (17.5% vs 16.5%).
Conclusions and Relevance In this phase 3 clinical trial of patients with advanced STS, treatment with doxorubicin plus olaratumab vs doxorubicin plus placebo resulted in no significant difference in overall survival. The findings did not confirm the overall survival benefit observed in the phase 2 trial.